Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9446135 | SHANDONG LUYE | Risperidone sustained release microsphere composition |
Apr, 2032
(7 years from now) | |
US11110094 | SHANDONG LUYE | Risperidone sustained release microsphere composition |
Apr, 2032
(7 years from now) | |
US10406161 | SHANDONG LUYE | Risperidone sustained release microsphere composition |
Apr, 2032
(7 years from now) | |
US10098882 | SHANDONG LUYE | Risperidone sustained release microsphere composition |
Apr, 2032
(7 years from now) | |
US9532991 | SHANDONG LUYE | Risperidone sustained release microsphere composition |
Apr, 2032
(7 years from now) |
Rykindo is owned by Shandong Luye.
Rykindo contains Risperidone.
Rykindo has a total of 5 drug patents out of which 0 drug patents have expired.
Rykindo was authorised for market use on 13 January, 2023.
Rykindo is available in for suspension, extended release;intramuscular dosage forms.
Rykindo can be used as treatment of schizophrenia in adults.
The generics of Rykindo are possible to be released after 10 April, 2032.
Drugs and Companies using RISPERIDONE ingredient
Market Authorisation Date: 13 January, 2023
Treatment: Treatment of schizophrenia in adults
Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR